DDrare: Database of Drug Development for Rare Diseases

Searched query = "Pituitary gonadotropin secretion hyperthyroidism", "Gonadotropin secreting pituitary adenoma", "Central precocious puberty", "Gonadotropin producing pituitary adenoma"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Acetate; CPP; Dabu ying pills; Dihuang; Enantone; GnRH; GnRH agonist; Gold; Gonadorelin; Gonadorelin acetate and Triptorelin acetate; Histrelin; Histrelin Subcutaneous Implant; LA; LEUPRORELIN ACETATE; Leuplin; Leuplin DPS 11.25mg; Leuprolide; Leuprolide (GnRH agonists); Leuprolide Acetate (LA); Leuprolide Acetate 3 Month Depot; Leuprolide Acetate 45 mg; Leuprolide acetate 11.25 mg; Leuprolide acetate 30 mg; Leuprolide acetate depot; Leuprorelin; Leuprorelin Acetate 3.75mg Injection; Luphere depot 3.75mg(Leuprolide acetate 3.75mg); Lupron (leuprolide acetate); Megestrol Acetate Tablet; Megestrol acetate; RhGH; TRIPTORELIN; Trade name depends on the source of the product; Trade name depends on the source of the product’; Triptorelin; Triptorelin (GnRH agonists); Triptorelin acetate and Gonadorelin acetate; Triptorelin embonate, Triptorelin pamoate; Triptorlin or Leuprorelin; Zhibo dihuang pills; Ziyinxiehuo Granules Herbs

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-001607-30-Outside-EU/EEA (EUCTR)		24/04/2015	Triptorelin 6-month formulation for children who mature too early because of a brain hormone	An open-label, non-comparative, multicenter study on the efficacy, safety, and pharmacokinetics of triptorelin pamoate (embonate) 22.5 mg 6-month formulation in patients suffering from central (gonadotropin-dependent) precocious puberty - Triptorelin 6-month Formulation in Patients With Central Precocious Puberty	Central Precocious Puberty MedDRA version: 18.0;Level: PT;Classification code 10058084;Term: Precocious puberty;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Body processes [G] - Biological Phenomena [G16]	INN or Proposed INN: TRIPTORELIN Other descriptive name: Triptorelin embonate, Triptorelin pamoate	Debiopharm International, S.A.	NULL	NA			Female: yes Male: yes	44		United States;Chile;Mexico

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2015-001607-30-Outside-EU/EEA
(EUCTR)

24/04/2015

Triptorelin 6-month formulation for children who mature too early because of a brain hormone

An open-label, non-comparative, multicenter study on the efficacy, safety, and pharmacokinetics of triptorelin pamoate (embonate) 22.5 mg 6-month formulation in patients suffering from central (gonadotropin-dependent) precocious puberty - Triptorelin 6-month Formulation in Patients With Central Precocious Puberty

Central Precocious Puberty
MedDRA version: 18.0;Level: PT;Classification code 10058084;Term: Precocious puberty;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Body processes [G] - Biological Phenomena [G16]

INN or Proposed INN: TRIPTORELIN
Other descriptive name: Triptorelin embonate, Triptorelin pamoate

Debiopharm International, S.A.

NULL

Female: yes
Male: yes

United States;Chile;Mexico